Presentation TCT 2024 Real World TTVI Registries vs. Randomized Trials: Are the Outcomes Aligned? Presenter: Brian Whisenant October 30, 2024
Presentation TCT 2024 Transcatheter Tricuspid Valve Replacement - Lessons Learned From TRISCEND II Presenter: Charles Davidson October 30, 2024
Presentation TCT 2024 Quantitative Flow Ratio or Fractional Flow Reserve for Guiding Coronary Revascularization Presenter: Birgitte Krogsgaard Andersen October 30, 2024
Presentation TCT 2024 Transcatheter Tricuspid Edge-To-Edge-Repair – Updates from TRILUMINATE and TRI-FR Presenter: Paul Sorajja October 30, 2024
Presentation TCT 2024 One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial Presenter: Michael Reardon October 30, 2024
Presentation TCT 2024 TCT 346: Assessment of Long-Term Clinical Outcomes of De Novo DCB Performance: Patient Data Meta-Analysis of Randomized Clinical Trials: Final Results of the ANDROMEDA Study Presenter: Bernardo Cortese October 30, 2024
Presentation TCT 2024 Lessons Learned From Recent Clinical Trials (EARLY TAVR and AVATAR) Presenter: Allan Schwartz October 30, 2024
Presentation TCT 2024 A Critical Review of Clinical Results in Current TMVR Trials: Implications for Patient Selection and Study Design Presenter: Firas Zahr October 30, 2024
Presentation TCT 2024 Transcatheter Repair Versus Surgery in Atrial Mitral Regurgitation: Results From the MATTERHORN Trial Presenter: Stephan Baldus October 30, 2024
Presentation TCT 2024 DANGER Shock: Impella versus Standard Card for STEMI Patients with Cardiogenic Shock Presenter: Jacob Moeller October 30, 2024
Presentation TCT 2024 CLASP IID Randomized Trial and Registry: Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation Presenter: Firas Zahr October 30, 2024
Presentation TCT 2024 Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: The CLEAR IE Multicenter Registry Presenter: Abdallah El Sabbagh October 30, 2024
Presentation TCT 2024 The TARGET-IV Trial: International Multicenter Randomized Assessment of the Firehawk® Rapamycin Eluting Coronary Stent System Presenter: Olivier Bertrand October 30, 2024
Presentation TCT 2024 3-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of the Biodegradable Polymer Firehawk Sirolimus-Eluting Coronary Stent: Primary Outcomes of the TARGET DAPT Trial Presenter: Hongbo Yang October 30, 2024